Drug:
Reaction: DERMATITIS ATOPIC
20250101 - 20251231
No. 501 - 600
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 501 | 25099860 |
US |
37 | 2 |
Dermatitis atopic, Rash erythematous, Pruritus, |
||||
DUPILUMAB, |
||||
| 502 | 25099975 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 503 | 25099976 |
US |
4 | 1 |
Scratch, Rash, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 504 | 25100056 |
US |
54 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 505 | 25100177 |
US |
69 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 506 | 25100391 |
US |
42 | 2 |
Dermatitis atopic, Skin irritation, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 507 | 25100449 |
US |
16 | 2 |
Dermatitis atopic, |
||||
ABROCITINIB, |
||||
| 508 | 25100544 |
US |
66 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 509 | 25100545 |
US |
75 | 1 |
Dermatitis atopic, Pruritus, Erythema, |
||||
DUPILUMAB, |
||||
| 510 | 25100546 |
US |
1 | |
Influenza, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 511 | 25100619 |
US |
31 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 512 | 25100643 |
US |
||
Psoriatic arthropathy, Dermatitis atopic, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 513 | 25100937 |
US |
||
Skin exfoliation, Eye swelling, Eye pruritus, Erythema, Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 514 | 25100940 |
US |
||
Dermatitis atopic, |
||||
NEMOLIZUMAB-ILTO, NEMOLIZUMAB-ILTO, |
||||
| 515 | 25101038 |
US |
||
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 516 | 25101043 |
US |
||
Dermatitis atopic, Product dose omission issue, |
||||
NEMOLIZUMAB-ILTO, |
||||
| 517 | 25101163 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 518 | 25101299 |
US |
44 | 1 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 519 | 25101332 |
US |
2 | |
Dermatitis atopic, Off label use, |
||||
DUPILUMAB, |
||||
| 520 | 25101475 |
US |
5 | 2 |
Dermatitis atopic, Rash, |
||||
DUPILUMAB, |
||||
| 521 | 25101612 |
US |
9 | 2 |
Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 522 | 25101808 |
US |
64 | 1 |
Sleep disorder due to a general medical condition, Dermatitis atopic, Pruritus, Skin haemorrhage, Skin weeping, Skin fissures, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 523 | 25101811 |
US |
18 | 1 |
Impetigo, Dermatitis atopic, Seborrhoeic dermatitis, |
||||
UPADACITINIB, |
||||
| 524 | 25102149 |
US |
25 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 525 | 25102332 |
US |
48 | 2 |
Dermatitis atopic, Nasal polyps, Asthma, Product dose omission in error, Condition aggravated, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 526 | 25102410 |
US |
40 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 527 | 25102411 |
US |
2 | |
Hyperhidrosis, Dermatitis atopic, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 528 | 25092131 |
DE |
1 | |
Erysipelas, Nasopharyngitis, Tinea pedis, Dermatitis atopic, Cystitis, Seborrhoeic dermatitis, |
||||
BIMEKIZUMAB, |
||||
| 529 | 25092151 |
US |
49 | 2 |
Eczema, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 530 | 25092470 |
US |
62 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 531 | 25092487 |
US |
2 | |
Dermatitis allergic, Dermatitis atopic, Condition aggravated, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 532 | 25092530 |
US |
63 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 533 | 25092533 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 534 | 25092540 |
US |
52 | 2 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 535 | 25092699 |
US |
2 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 536 | 25092808 |
US |
78 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 537 | 25092899 |
US |
2 | |
Skin burning sensation, Blister, Dermatitis atopic, Bone pain, Dry skin, |
||||
DUPILUMAB, DUPILUMAB, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 538 | 25092976 |
US |
77 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 539 | 25092978 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, LEBRIKIZUMAB-LBKZ, |
||||
| 540 | 25093178 |
US |
55 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 541 | 25093339 |
US |
67 | 1 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, NIVOLUMAB, |
||||
| 542 | 25093721 |
US |
53 | 1 |
Dermatitis atopic, Pruritus, Rash, |
||||
DUPILUMAB, |
||||
| 543 | 25093728 |
US |
25 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 544 | 25093733 |
US |
18 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 545 | 25093740 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 546 | 25093747 |
US |
2 | |
Dermatitis atopic, Dry skin, Skin fissures, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 547 | 25093752 |
US |
22 | 2 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 548 | 25093753 |
US |
1 | |
Dermatitis atopic, Drug ineffective, |
||||
DUPILUMAB, |
||||
| 549 | 25093762 |
US |
47 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 550 | 25093765 |
US |
60 | 2 |
Dermatitis atopic, Pain, Drug effect less than expected, |
||||
DUPILUMAB, |
||||
| 551 | 25093778 |
US |
64 | 2 |
Dermatitis atopic, Stress, |
||||
DUPILUMAB, |
||||
| 552 | 25093784 |
US |
53 | 1 |
Dermatitis atopic, Pruritus, |
||||
DUPILUMAB, |
||||
| 553 | 25093785 |
US |
64 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 554 | 25093791 |
US |
26 | 2 |
Dry skin, Dermatitis atopic, Therapeutic response shortened, Skin fissures, Skin haemorrhage, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 555 | 25093804 |
US |
23 | 2 |
Dermatitis atopic, Product dose omission in error, |
||||
DUPILUMAB, |
||||
| 556 | 25093976 |
US |
1 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 557 | 25094020 |
US |
76 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 558 | 25094024 |
US |
51 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 559 | 25094028 |
US |
2 | |
Blister, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 560 | 25094082 |
US |
45 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 561 | 25094086 |
US |
62 | 1 |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 562 | 25094101 |
US |
29 | 2 |
Rash erythematous, Burning sensation, Pruritus, Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 563 | 25094336 |
US |
2 | |
Dermatitis atopic, Therapeutic response shortened, |
||||
DUPILUMAB, |
||||
| 564 | 25094338 |
US |
22 | 2 |
Dermatitis atopic, Stress, |
||||
DUPILUMAB, |
||||
| 565 | 25094393 |
US |
40 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 566 | 25094450 |
US |
4 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 567 | 25094693 |
US |
63 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 568 | 25094729 |
US |
53 | 2 |
Polymyalgia rheumatica, Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, METHYLPREDNISOLONE, METHYLPREDNISOLONE, METHOTREXATE, METHOTREXATE SODIUM, ERGOCALCIFEROL, MONTELUKAST SODIUM, METHYLPREDNISOLONE, TAMOXIFEN CITRATE, METFORMIN HYDROCHLORIDE, METFORMIN, METFORMIN HYDROCHLORIDE EXTENDED-RELEASE TABLETS, METFORMIN HYDROCHLORIDE TABLET, METFORMIN HYDROCHLORIDE TABLETS, VENLAFAXINE HYDROCHLORIDE, |
||||
| 569 | 25094783 |
US |
33 | 1 |
Dermatitis atopic, Rash pruritic, |
||||
DUPILUMAB, |
||||
| 570 | 25094910 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 571 | 25094911 |
US |
8 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, OSELTAMIVIR PHOSPHATE, OSELTAMIVIR ACID, OSELTAMIVIR, |
||||
| 572 | 25095072 |
US |
65 | 2 |
Lacrimation increased, Abnormal sensation in eye, Sleep disorder due to a general medical condition, Pruritus, Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 573 | 25095529 |
US |
56 | 1 |
Dermatitis atopic, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 574 | 25095531 |
US |
34 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 575 | 25095534 |
US |
62 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 576 | 25095765 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 577 | 25095767 |
US |
2 | |
Dermatitis atopic, Condition aggravated, Therapeutic response decreased, |
||||
DUPILUMAB, |
||||
| 578 | 25095824 |
US |
2 | |
Dry skin, Dermatitis atopic, |
||||
DUPILUMAB, LEVONORGESTREL, |
||||
| 579 | 25095825 |
US |
47 | 2 |
Dermatitis atopic, Rash erythematous, Skin burning sensation, Pruritus, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 580 | 25095829 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, LEVONORGESTREL, |
||||
| 581 | 25096149 |
US |
23 | 2 |
Dermatitis atopic, Therapeutic response shortened, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 582 | 25096150 |
US |
1 | |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 583 | 25096864 |
US |
32 | 1 |
Application site erythema, Rash, Burning sensation, Erythema, Dermatitis atopic, Intertrigo, Rash, |
||||
| 584 | 25096887 |
US |
21 | 2 |
Dermatitis atopic, Incorrect dose administered, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 585 | 25097053 |
US |
81 | 2 |
Knee operation, Dermatitis atopic, |
||||
UPADACITINIB, |
||||
| 586 | 25097149 |
US |
67 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 587 | 25087247 |
US |
52 | 2 |
Dermatitis atopic, |
||||
TRALOKINUMAB-LDRM, |
||||
| 588 | 25091011 |
CA |
36 | 2 |
Injection site erythema, Psoriasis, Seborrhoeic dermatitis, Dermatitis atopic, COVID-19, Arthritis, Viral upper respiratory tract infection, Scar, Needle issue, Inappropriate schedule of product administration, Influenza, Dermatitis, Headache, Nausea, |
||||
HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, HUMAN IMMUNOGLOBULIN G, UPADACITINIB, GOLIMUMAB, LEVOTHYROXINE SODIUM, SULFASALAZINE, |
||||
| 589 | 25091349 |
US |
47 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 590 | 25091352 |
US |
32 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 591 | 25091362 |
US |
21 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 592 | 25091365 |
US |
84 | 1 |
Dermatitis atopic, Inappropriate schedule of product administration, |
||||
DUPILUMAB, |
||||
| 593 | 25091373 |
US |
46 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 594 | 25091376 |
US |
36 | 1 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 595 | 25091380 |
US |
52 | 1 |
Dermatitis atopic, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 596 | 25091406 |
US |
2 | |
Dermatitis atopic, |
||||
DUPILUMAB, LEVONORGESTREL, |
||||
| 597 | 25091409 |
US |
17 | 2 |
Injection site pain, Dermatitis atopic, Skin swelling, Skin irritation, Anxiety, Inappropriate schedule of product administration, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 598 | 25091418 |
US |
56 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 599 | 25091429 |
US |
36 | 2 |
Dermatitis atopic, |
||||
DUPILUMAB, |
||||
| 600 | 25091433 |
US |
24 | 1 |
Dermatitis atopic, Accidental exposure to product, Exposure via skin contact, |
||||
DUPILUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2025-04-28